MedTrace Logo

Atrial Fibrillation: Risk and Benefits of Anti-coagulation in the Elderly

NCT03828162 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2943

Last updated 2019-02-04

No results posted yet for this study

Summary

This study was designed to assess the effectiveness of oral anticoagulants in elderly patients (\>=75 years) with atrial fibrillation. All patients discharged from one large hospital in Stockholm, Danderyds Hospital, between november 1st 2010 and december 31st 2017 with atrial fibrillation as main diagnosis have been included (n=2943). Adverse events (cardiovascular death, fatal/non fatal ischemic stroke, peripheral thromboembolism, fatal/non fatal intracerebral hemorrhage and extracranial bleeding) are recorded through linkage to mandatory and qualitative national registries and review of the medical records until december 31 2018.

Conditions

  • Anticoagulants Causing Adverse Effects in Therapeutic Use
  • Atrial Fibrillation
  • Frail Elderly Syndrome

Interventions

DRUG

Anticoagulants

Sponsors & Collaborators

Principal Investigators

  • Bruna Gigante, MD PhD · Karolinska Institutet

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-01
Primary Completion
2017-12-31
Completion
2018-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03828162 on ClinicalTrials.gov